Target Name: CD163
NCBI ID: G9332
Review Report on CD163 Target / Biomarker Content of Review Report on CD163 Target / Biomarker
CD163
Other Name(s): Macrophage-associated antigen | SCARI1 | macrophage-associated antigen | Soluble CD163 | CD163 molecule | Scavenger receptor cysteine-rich type 1 protein M130 (isoform a) | CD163 molecule, transcript variant 1 | Scavenger receptor cysteine-rich type 1 protein M130 (isoform b) | MM130 | CD163 variant 1 | Hemoglobin scavenger receptor | M130 | sCD163 | CD163 molecule, transcript variant 2 | C163A_HUMAN | sCD163_(HUMAN) | Scavenger receptor cysteine-rich type 1 protein M130 | CD163 variant 2 | hemoglobin scavenger receptor

CD163: A Promising Drug Target and Biomarker for Macrophage-Associated Anomalies

Introduction

Macrophage-associated antigens (MAAs) are a diverse family of proteins that play a crucial role in the immune system, specifically in the regulation of inflammation and tissue homeostasis. MAAs are expressed in various cell types, including macrophages, and are involved in various cellular processes, such as cell adhesion, migration, and intracellular signaling. The identification and characterization of new MAAs is crucial for understanding the mechanisms underlying immune and inflammatory diseases.

One of the growing areas of research is the exploration of MAAs as potential drug targets or biomarkers. CD163, a MAA highly expressed in macrophages, has been identified as a promising drug target in various diseases, including cancer, inflammation, and autoimmune disorders. In this article, we will discuss the biology of CD163, its potential as a drug target, and its potential as a biomarker for various diseases.

The biology of CD163

CD163 is a 16kDa protein that is highly expressed in macrophages, with up to 50% of macrophages positive for CD163. CD163 is a member of the CD163 family, which includes several other MAAs, including CD163A, CD163B, and CD163C (2 ). CD163 is involved in various cellular processes, including cell adhesion, migration, and intracellular signaling.

CD163 functions as a receptor for various cytokines and chemokines, including TLR-4, TLR-6, 鈥嬧?媋nd PD-1. TLR-4 and TLR-6 are involved in the innate immune response, while PD-1 is involved in the adaptive immune response. These interactions between CD163 and cytokines/chemokines play a crucial role in the regulation of immune and inflammatory responses.

CD163 is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway. TGF-β is a well-established regulator of cell proliferation and differentiation, and its dysfunction has been implicated in various diseases, including cancer. The regulation of TGF-β by CD163 may have implications for the development and progression of these diseases.

CD163 has also been shown to play a role in the regulation of cellular apoptosis. Apoptosis is a natural aspect of cellular life cycle that is regulated by various signaling pathways, including the TGF-β pathway. The regulation of apoptosis by CD163 may have implications for the regulation of cellular aging and the aging process.

Potential as a drug target

CD163's involvement in various cellular processes makes it an attractive target for drug development. The functions of CD163 as a receptor for cytokines and chemokines, as well as its involvement in the regulation of cellular signaling pathways and apoptosis, suggest that it may be a useful target for the treatment of various diseases.

One of the main advantages of CD163 as a drug target is its druggability. The CD163 protein is known to have several potential drug-like molecules that can interact with it, including small molecules, peptides, and antibodies. These molecules have been shown to be effective in various cellular assays, including cell-based assays and in animal models of disease.

CD163 has also been shown to play a role in the regulation of inflammation and cancer. Its involvement in the regulation of TGF-β and the regulation of apoptosis may have implications for the development and progression of these diseases.

In addition to its potential as a drug target, CD163 has also been shown to be a potential biomarker for various diseases. Its high expression in macrophages makes it an

Protein Name: CD163 Molecule

Functions: Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron, via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization, inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells

The "CD163 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD163 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C